Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth
Portfolio Pulse from
Seeking Alpha's Stock Screener suggests selling six overvalued blue-chip stocks due to high valuations and limited growth potential. The stocks include Costco, Cencora, West Pharmaceutical Services, Danaher, Madison Square Garden Sports, and Estée Lauder. These stocks have shown weakening performance compared to the S&P 500 since summer.
January 13, 2025 | 5:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cencora is identified as overvalued with limited growth potential, showing weakening performance against the S&P 500.
Cencora's high valuation and limited growth potential, along with its underperformance compared to the S&P 500, suggest a bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Costco is identified as overvalued with limited growth potential, showing weakening performance against the S&P 500.
Costco's high valuation and limited growth potential, along with its underperformance compared to the S&P 500, suggest a bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Danaher is identified as overvalued with limited growth potential, showing weakening performance against the S&P 500.
Danaher's high valuation and limited growth potential, along with its underperformance compared to the S&P 500, suggest a bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Estée Lauder is identified as overvalued with limited growth potential, showing weakening performance against the S&P 500.
Estée Lauder's high valuation and limited growth potential, along with its underperformance compared to the S&P 500, suggest a bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Madison Square Garden Sports is identified as overvalued with limited growth potential, showing weakening performance against the S&P 500.
Madison Square Garden Sports' high valuation and limited growth potential, along with its underperformance compared to the S&P 500, suggest a bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
West Pharmaceutical Services is identified as overvalued with limited growth potential, showing weakening performance against the S&P 500.
West Pharmaceutical's high valuation and limited growth potential, along with its underperformance compared to the S&P 500, suggest a bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80